Does your GLP-1 injection site actually change your results?

What did @my.journey.with.marc actually say?

Mark claims that switching his injection site from stomach to alternating thighs was "a complete game changer" for his results on tirzepatide (Mounjaro). He says craving control felt more consistent, side effects were smoother, and that most people make the mistake of picking one site and never testing others. His advice: try each approved injection area for a few weeks, track how you feel, then alternate within your best site.

To his credit, he repeatedly frames this as personal experience, not medical advice. He's not telling you thighs are objectively superior. He's telling you to experiment and pay attention. That's actually a reasonable position, even if the biological rationale behind it is murkier than he implies.

Does the science back this up?

Partly, but the evidence is thinner than the TikTok confidence suggests. Injection site does affect drug absorption, and that's documented. The question is whether those differences are clinically meaningful for most people.

A pharmacokinetic review by Frid et al. (2016, Diabetes Care) confirmed that subcutaneous absorption of injectable medications varies by site, with abdominal tissue generally producing faster absorption than thigh or arm. For GLP-1 receptor agonists specifically, the FDA-approved labeling for both semaglutide (Wegovy) and tirzepatide (Mounjaro) permits injection into the abdomen, thigh, or upper arm, without specifying one as superior.

A 2022 analysis by Bergenstal et al. in Diabetes Technology and Therapeutics looked at variability in subcutaneous drug delivery and found that lipohypertrophy (scar tissue buildup from repeated injections in the same spot) meaningfully reduces absorption. This is the strongest scientific argument for rotating sites, and it's one Mark implicitly makes without naming it. There is no published randomized controlled trial directly comparing thigh versus abdomen injection outcomes for tirzepatide or semaglutide in terms of weight loss or appetite control.

What did they get wrong (or right)?

Mark gets the rotation principle right, and that matters. The part that deserves scrutiny is the implied causal link between his thigh switch and his improved results.

He lost 9 stone in under a year. That's a substantial result by any measure. But attributing improved craving control specifically to his injection site, rather than to dose escalation, dietary changes, adaptation to the medication, or simple placebo effect, is a leap the data doesn't support. He doesn't acknowledge those confounders, and that's where the video misleads by omission.

The claim that "you can respond slightly differently depending on the site" is biologically plausible but not proven in the GLP-1 context. Faster absorption from the abdomen does not straightforwardly translate to better appetite suppression, since semaglutide and tirzepatide have long half-lives (roughly 7 days and 5 days respectively) that smooth out absorption differences over the dosing interval.

He also never mentions lipohypertrophy by name, which is arguably the most clinically important reason to rotate sites. That's a real gap for an audience that may not know what to look for.

What should you actually know?

Rotation within and across approved sites is genuinely recommended, and not just for comfort. Injecting repeatedly into the same spot can cause fatty tissue buildup that impairs absorption, and that is documented in the insulin literature and applicable to GLP-1 injectables.

The three approved sites for both Mounjaro and Wegovy are the abdomen (at least two inches from the navel), the upper thigh, and the outer upper arm. Rotating between and within these areas reduces the risk of lipohypertrophy and injection site reactions.

What you should not do is assume that one site will produce dramatically better weight loss or craving control than another. Individual variation in subcutaneous fat depth, local blood flow, and tissue health matters more than which body region you choose. If you notice a site consistently producing more discomfort, bruising, or swelling, that's worth raising with your prescriber, not just switching to thighs because Mark had a good experience.

• Always inspect your injection site for lumps or hardened tissue before injecting.
• Rotate at least one inch from your previous injection point within the same region.
• Talk to your prescriber if you think absorption feels inconsistent. There are clinical reasons this can happen.